Keywords: merck, co, gains, eu, appro, janumet, drug
Merck & Co gains EU appro for Janumet
Article | 28 July 2008
US drug major Merck & Co has been granted European marketing authorization for type 2 diabetes treatment Janumet (sitagliptin/metformin).
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
